Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study

Author(s): Achiron A, Chapman J, Magalashvili D, Dolev M, Lavie M, et al.

Abstract

Background/aims:Large-scale population studies measuring rates and dynamics of cognitive decline in multiple sclerosis (MS) are lacking. In the current cross-sectional study we evaluated the patterns of cognitive impairment in MS patients with disease duration of up to 30 years.

Methods:1,500 patients with MS were assessed by a computerized cognitive battery measuring verbal and non-verbal memory, executive function, visual spatial perception, verbal function, attention, information processing speed and motor skills. Cognitive impairment was defined as below one standard deviation (SD) and severe cognitive impairment as below 2SD for age and education matched healthy population norms.

Results:Cognitive performance in our cohort was poorer than healthy population norms. The most frequently impaired domains were information processing speed and executive function. MS patients with secondary-progressive disease course performed poorly compared with clinically isolated syndrome, relapsing-remitting and primary progressive MS patients. By the fifth year from disease onset, 20.9% of patients performed below the 1SD cutoff for impairment, p=0.005, and 6.0% performed below the 2SD cutoff for severe cognitive impairment, p=0.002. By 10 years from onset 29.3% and 9.0% of patients performed below the 1SD and 2SD cutoffs, respectively, p=0.0001. Regression modeling suggested that cognitive impairment may precede MS onset by 1.2 years.

Conclusions:The rates of cognitive impairment in this large sample of MS patients were lower than previously reported and severe cognitive impairment was evident only in a relatively small group of patients. Cognitive impairment differed significantly from expected normal distribution only at five years from onset, suggesting the existence of a therapeutic window during which patients may benefit from interventions to maintain cognitive health.

Similar Articles

Prevalence and treatment of spasticity reported by multiple sclerosis patients

Author(s): Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL

Anti-spasticity agents for multiple sclerosis

Author(s): Shakespeare DT, Boggild M, Young C

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

Author(s): Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group

The endocannabinoid system and the brain

Author(s): Mechoulam R, Parker LA

Exploring the association between cannabis use and depression

Author(s): Degenhardt L, Hall W, Lynskey M

Impulsivity, attention, memory, and decision-making among adolescent marijuana users

Author(s): Dougherty DM, Mathias CW, Dawes MA, Furr RM, Charles N, et al.